SCHEMBL6177327

SCHEMBL6177327

CCc1nc(-c2ccccc2)cn1-c1ccc(CCN)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPNS2 Q8IVW8 2/20 0.43
TAAR1 Q96RJ0 3/20 0.40
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
MAPT P10636 2/20 0.40
LMNA P02545 2/20 0.40
PTGS2 P35354 1/20 0.39
HTR2A P28223 3/20 0.39
LOXL2 Q9Y4K0 2/20 0.39
CYP2A6 P11509 1/20 0.39
HSD11B1 P28845 1/20 0.38
AGER Q15109 1/20 0.38
TLR8 Q9NR97 2/20 0.37
TP53 P04637 1/20 0.36
PKM P14618 1/20 0.36
ALOX15 P16050 1/20 0.36
RECQL P46063 1/20 0.36
FAAH O00519 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6179004 0.87 AGER (0.42) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL6175993 0.87 PTGS2 (0.41) SPNS2NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL4447659 0.84 MAPT (0.41) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL6176352 0.81 ALDH1A1 (0.44) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL6177331 0.81 SMN1; SMN2 (0.39) TAAR1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL6179637 0.79 SMN1; SMN2 (0.37) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL6174933 0.78 TAAR1 (0.43) TAAR1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL6173846 0.76 AGER (0.54) SPNS2SMN1; SMN2MAPTHSD11B1AGER
SCHEMBL6177232 0.76 TAAR1 (0.48) TAAR1NPC1RAB9AMAPTPKM
SCHEMBL6178053 0.75 AGER (0.43) SPNS2NPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6956050-B2 Imidazole compounds as anti-inflammatory and analgesic agents PFIZER, INC. (US) 2005-10-18 US disclosed
EP-1494667-A1 IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS Pfizer Japan Inc. (JP) 2005-01-12 EP disclosed
US-20030220372-A1 Imidazole compounds as anti-inflammatory and analgesic agents HIRANO MISATO (JP) 2003-11-27 US disclosed
WO-2003086390-A1 IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER JAPAN INC. (JP) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220372-A1 Imidazole compounds as anti-inflammatory and analgesic agents PTGS1, PTGS2, PTGES SPNS2 4743/4885TAAR1 2861/4885NPC1 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.